Latest news with #veterinaryMedicine
CTV News
25-06-2025
- Health
- CTV News
Calgary Stampede rodeo safety to include shaded pens, heart monitors for horses
The Calgary Stampede is working with the University of Calgary's faculty of veterinary medicine on a few different studies. The Calgary Stampede is working with the University of Calgary's faculty of veterinary medicine on a few different studies. Tents are being set up to provide shade for bulls and broncs and some chuckwagon horses are to be fitted with tiny electrocardiograms at the upcoming Calgary Stampede. Based on scorching heat at the rodeo last summer, Ed Pajor, a professor of animal behaviour and welfare in the University of Calgary's faculty of veterinary medicine, says the animals could use a break. 'We saw things like increased respiration rate in some of the bulls. We saw some bulls drooling. These are signs that the animals might be experiencing some discomfort due to the heat,' Pajor said at a news conference Tuesday. The university is working with the Stampede to study some of the animals this year. They'll specifically look at whether bucking bulls and broncos will be happier and healthier if they have a shady place to hang out right before the competition. 'It seems like a pretty straightforward question,' said Pajor, adding if shade is beneficial, the Stampede would have to decide whether to invest in more tent coverings in the future. Additional research at the rodeo is to focus on the heart health of horses in the chuckwagon races. Dr. Renaud Léguillette with the university's veterinary school specializes in equine health and performance, and works closely with chuckwagon horses during the Stampede. His research includes identifying in equine blood a baseline for troponin — a protein released when the heart muscle is damaged — to track underlying cardiovascular or other health issues. 'The goal of our research is to prevent cardiac accidents during the chuckwagon racing due to a cardiac problem,' said Léguillette. 'There are some horses who have more electrical activity issues when they race or have a harder time to recover from the races.' At the Stampede, outrider horses and horses pulling the wagons are to be fitted with electrocardiograms before and during the races. Léguillette said the devices and the blood tests can show what horses are at a higher risk of cardiac arrest and that information is passed on to chuckwagon drivers. 'I call it like a green light, an orange light and a red light. The red light horses, I will definitely have a discussion with the drivers ... they are very responsive, concerned and will make the right decisions.' An official with the Stampede said research in this area could benefit an entire industry. 'We know there is an element of risk in all sport. Our goal is to create the safest conditions possible. That's why all of this research takes place ... to remove all of those elements of risk,' said Kristina Barnes, the Stampede's director of agriculture and western events. 'Can we remove completely that element of risk? No. But anything that we can control we certainly will.' The 10-day celebration of western culture, which runs from July 4-13, has long been a target of animal rights groups. The Vancouver Humane Society wants the rodeo portion of the Stampede eliminated. 'We're seeing deaths at the Calgary Stampede almost every single year. It's really not a matter of if another animal will die at the Stampede ... it's when,' said Chantelle Archambault with the group. 'Last year, there were four animal deaths. It also marks at least 109 animals deaths at the Stampede since we began tracking fatalities in 1986.' This report by The Canadian Press was first published June 24, 2025. Bill Graveland, The Canadian Press
Yahoo
23-06-2025
- Health
- Yahoo
NEL Animal Cardiovascular Center Achieves World's First Surgical Correction of Complex VSD in Canine Patient
ANYANG, South Korea, June 23, 2025--(BUSINESS WIRE)--NEL Animal Cardiovascular Center, a private 24-hour animal hospital in South Korea, said that its cardiac surgery team has successfully performed the world's first surgical correction of a complex ventricular septal defect (VSD) in a canine patient. This veterinary milestone is highly significant, as it marks the first such case not only in Korea but also globally, with no previous reports of successful surgical treatment for complex VSDs. The patient was diagnosed with a unique form of VSD—a single, continuous defect extending from the perimembranous to the subarterial region (Perimembranous VSD extending into subarterial region). Given that there had been no prior successful surgical cases even for typical VSDs in veterinary medicine, this breakthrough greatly expands the possibilities for surgical treatment of congenital heart disease in Korea's veterinary cardiac surgery field. Over the past year, NEL's cardiac surgery team has gained experience through more than 50 open-heart surgeries using cardiopulmonary bypass. Based on this expertise, the team developed a thorough surgical plan. During the procedure, the complex VSD involving both membranous and subarterial regions was confirmed. The team performed incisions in the right atrium and pulmonary artery, successfully closing the defect with a bovine pericardial patch. Immediately after surgery, the left-to-right shunt was completely resolved, and the risk of progressive regurgitation due to aortic valve prolapse was eliminated. The patient's cardiac function recovered to near-normal levels, and the long-term prognosis is considered highly favorable. Subarterial VSDs are particularly dangerous due to the risk of aortic valve prolapse and severe regurgitation, making early surgical intervention crucial. The success of this surgery offers new hope for animals with congenital heart defects, demonstrating the potential for a surgical cure. Dr. Tae-Heum Um, Director of NEL Animal Cardiovascular Center, stated, "Although this was a complex defect, thorough discussion and preparation among our medical team led to a successful outcome. We will continue our efforts so that more animals with congenital heart disease can lead healthy and normal lives." NEL Animal Cardiovascular Center is preparing an academic analysis and official report on this case, and sincerely hopes that this achievement contributes to the advancement of veterinary cardiac surgery not only in Korea, but also across Asia. View source version on Contacts NEL Animal Cardiovascular CenterYoon il-yong+82-31-421-7579heart@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
23-06-2025
- Health
- Associated Press
NEL Animal Cardiovascular Center Achieves World's First Surgical Correction of Complex VSD in Canine Patient
ANYANG, South Korea--(BUSINESS WIRE)--Jun 22, 2025-- NEL Animal Cardiovascular Center, a private 24-hour animal hospital in South Korea, said that its cardiac surgery team has successfully performed the world's first surgical correction of a complex ventricular septal defect (VSD) in a canine patient. This press release features multimedia. View the full release here: NEL Animal Cardiovascular Center's medical staff performing surgical correction of a complex ventricular septal defect (VSD) in a canine patient (Photo: NEL Animal Cardiovascular Center) This veterinary milestone is highly significant, as it marks the first such case not only in Korea but also globally, with no previous reports of successful surgical treatment for complex VSDs. The patient was diagnosed with a unique form of VSD—a single, continuous defect extending from the perimembranous to the subarterial region (Perimembranous VSD extending into subarterial region). Given that there had been no prior successful surgical cases even for typical VSDs in veterinary medicine, this breakthrough greatly expands the possibilities for surgical treatment of congenital heart disease in Korea's veterinary cardiac surgery field. Over the past year, NEL's cardiac surgery team has gained experience through more than 50 open-heart surgeries using cardiopulmonary bypass. Based on this expertise, the team developed a thorough surgical plan. During the procedure, the complex VSD involving both membranous and subarterial regions was confirmed. The team performed incisions in the right atrium and pulmonary artery, successfully closing the defect with a bovine pericardial patch. Immediately after surgery, the left-to-right shunt was completely resolved, and the risk of progressive regurgitation due to aortic valve prolapse was eliminated. The patient's cardiac function recovered to near-normal levels, and the long-term prognosis is considered highly favorable. Subarterial VSDs are particularly dangerous due to the risk of aortic valve prolapse and severe regurgitation, making early surgical intervention crucial. The success of this surgery offers new hope for animals with congenital heart defects, demonstrating the potential for a surgical cure. Dr. Tae-Heum Um, Director of NEL Animal Cardiovascular Center, stated, 'Although this was a complex defect, thorough discussion and preparation among our medical team led to a successful outcome. We will continue our efforts so that more animals with congenital heart disease can lead healthy and normal lives.' NEL Animal Cardiovascular Center is preparing an academic analysis and official report on this case, and sincerely hopes that this achievement contributes to the advancement of veterinary cardiac surgery not only in Korea, but also across Asia. View source version on CONTACT: NEL Animal Cardiovascular Center Yoon il-yong +82-31-421-7579 [email protected] KEYWORD: ASIA PACIFIC SOUTH KOREA INDUSTRY KEYWORD: CARDIOLOGY VETERINARY BIOTECHNOLOGY PETS SURGERY HEALTH HEALTH TECHNOLOGY CONSUMER SOURCE: NEL Animal Cardiovascular Center Copyright Business Wire 2025. PUB: 06/22/2025 08:00 PM/DISC: 06/22/2025 07:59 PM
Yahoo
23-06-2025
- Health
- Yahoo
NEL Animal Cardiovascular Center Achieves World's First Surgical Correction of Complex VSD in Canine Patient
ANYANG, South Korea, June 23, 2025--(BUSINESS WIRE)--NEL Animal Cardiovascular Center, a private 24-hour animal hospital in South Korea, said that its cardiac surgery team has successfully performed the world's first surgical correction of a complex ventricular septal defect (VSD) in a canine patient. This veterinary milestone is highly significant, as it marks the first such case not only in Korea but also globally, with no previous reports of successful surgical treatment for complex VSDs. The patient was diagnosed with a unique form of VSD—a single, continuous defect extending from the perimembranous to the subarterial region (Perimembranous VSD extending into subarterial region). Given that there had been no prior successful surgical cases even for typical VSDs in veterinary medicine, this breakthrough greatly expands the possibilities for surgical treatment of congenital heart disease in Korea's veterinary cardiac surgery field. Over the past year, NEL's cardiac surgery team has gained experience through more than 50 open-heart surgeries using cardiopulmonary bypass. Based on this expertise, the team developed a thorough surgical plan. During the procedure, the complex VSD involving both membranous and subarterial regions was confirmed. The team performed incisions in the right atrium and pulmonary artery, successfully closing the defect with a bovine pericardial patch. Immediately after surgery, the left-to-right shunt was completely resolved, and the risk of progressive regurgitation due to aortic valve prolapse was eliminated. The patient's cardiac function recovered to near-normal levels, and the long-term prognosis is considered highly favorable. Subarterial VSDs are particularly dangerous due to the risk of aortic valve prolapse and severe regurgitation, making early surgical intervention crucial. The success of this surgery offers new hope for animals with congenital heart defects, demonstrating the potential for a surgical cure. Dr. Tae-Heum Um, Director of NEL Animal Cardiovascular Center, stated, "Although this was a complex defect, thorough discussion and preparation among our medical team led to a successful outcome. We will continue our efforts so that more animals with congenital heart disease can lead healthy and normal lives." NEL Animal Cardiovascular Center is preparing an academic analysis and official report on this case, and sincerely hopes that this achievement contributes to the advancement of veterinary cardiac surgery not only in Korea, but also across Asia. View source version on Contacts NEL Animal Cardiovascular CenterYoon il-yong+82-31-421-7579heart@
Health Line
13-06-2025
- Health
- Health Line
Can Antiparasitic Drug Fenbendazole Treat Pancreatic Cancer?
Antiparasitic drugs such as fenbendazole have caught the attention of researchers studying pancreatic cancer. In early studies, they have shown promise in inhibiting the growth and spread of cancer cells. Pancreatic cancer is one of the most aggressive forms of cancer, with low survival rates. This disease is known for its late stage diagnosis and limited treatment options. As a result, researchers are constantly looking for new approaches to manage it. While several early studies have provided initial evidence suggesting that fenbendazole (Panacur, Safe-Guard) has potential in treating various types of cancer, including pancreatic cancer, further research is needed to determine its success and safety in human clinical trials. Let's go over existing research and evidence surrounding the use of fenbendazole for pancreatic cancer. What is fenbendazole? Fenbendazole is a broad-spectrum anthelmintic medication primarily used in veterinary medicine to treat animal gastrointestinal parasites. It belongs to the benzimidazole class of medications and is effective against various parasites, including roundworms, hookworms, whipworms, and certain animal tapeworms. While fenbendazole was initially formulated for veterinary use, preliminary research suggests that it may prevent cancer cell growth and induce cancer cell death. Fenbendazole is a veterinary medication and has not been approved by the Food and Drug Administration (FDA) for cancer treatment in humans. The use of fenbendazole for pancreatic cancer is still experimental, and more studies are needed to determine its success and safety in humans. Fenbendazole for pancreatic cancer Although there's limited research specifically focused on fenbendazole for pancreatic cancer, several studies have explored its anticancer properties in general. But the research is still in its early stages, and more research, including clinical trials, is needed to determine its success and safety in people with pancreatic cancer. Microtubule disruptor While the exact mechanisms behind fenbendazole's potential anticancer effects are still being studied, researchers suggest that fenbendazole may disrupt microtubules, which are structures involved in cell division and growth. Mebendazole Various studies are exploring another anthelmintic medication, this one formulated for humans, called mebendazole for its potential anticancer properties. While mebendazole belongs to the same class of medications as fenbendazole and may share some similarities in their potential anticancer properties, they aren't the same. A 2022 study highlighted the potential of mebendazole in combination with the targeted therapy drug bevacizumab for treating advanced colorectal cancer. Although this study focused on colorectal cancer, the findings suggest that mebendazole's anticancer activity extends to other types of cancer, including pancreatic cancer. If you're considering fenbendazole or mebendazole for pancreatic cancer treatment, consider speaking with a healthcare professional who can guide you on the most appropriate treatment based on your condition. Fenbendazole cancer clinical trials Currently, limited information is available about ongoing clinical trials specifically investigating the use of fenbendazole in cancer treatment. Most research on fenbendazole's potential anticancer effects has been preclinical or observational studies in animal models and cell cultures. Although these studies have shown promising results, the available evidence is still at its early stages, and more long-term research, including clinical trials, is needed to determine the safety and success of fenbendazole as a therapeutic option for cancer treatment. The goals of these clinical trials would be to determine the appropriate dosage and treatment regimen of fenbendazole for different types of cancer, assess its success compared with standard treatments, and test its safety in people with pancreatic cancer. What are the most successful treatments for pancreatic cancer? Pancreatic cancer is a challenging disease to treat, and treatment options can vary depending on the stage and characteristics of the cancer. But some of the most successful treatments for pancreatic cancer include: Surgery Surgical intervention is vital in treating pancreatic cancer, particularly for localized tumors. Surgery aims to remove the tumor and any affected surrounding tissue. A doctor may perform various surgical procedures based on the extent of the disease. Radiation therapy Radiation therapy uses high-energy X-rays to target and destroy cancer cells. It can be used before surgery, after surgery, or as palliative treatment to improve quality of life and relieve symptoms. Chemotherapy Chemotherapy uses medications to destroy cancer cells or hinder their growth. It can be administered before or after surgery or as the primary treatment for advanced pancreatic cancer. Common chemotherapy drugs for pancreatic cancer may include gemcitabine and nab-paclitaxel. Immunotherapy Immunotherapy uses the body's immune system to fight cancer. It involves medications that activate the immune system to recognize and attack cancer cells. While still being explored in clinical trials, immunotherapy has shown promise as a treatment option for certain types of pancreatic cancer. Palliative care This focuses on improving the quality of life for people with advanced pancreatic cancer. It aims to alleviate various symptoms and support the management of emotional and psychological challenges. It can also be given alongside curative treatments.
